arrow copy Created with Sketch. FightCRC Logo fcc-logo-light

Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location IO -centered Prior IO Allowed CRC-directed Status Drugs Tags
NCT05198934
Phase 3
2022-01-20
Alabama, United States
California, United States
District of Columbia, United States
Florida, United States
Georgia, United States
Michigan, United States
New York, United States
North Carolina, United States
Ohio, United States
Pennsylvania, United States
Tennessee, United States
Texas, United States
Australia
France
Germany
Greece
Italy
Japan
Korea, Republic of
Mexico
Spain
Taiwan
United Kingdom
No
Yes
Yes
Active, not recruiting
MSS/ pMMR
NCT04793958
Phase 3
2021-03-11
Alabama, United States
Arizona, United States
Arkansas, United States
California, United States
Colorado, United States
Connecticut, United States
Florida, United States
Georgia, United States
Illinois, United States
Indiana, United States
Iowa, United States
Louisiana, United States
Maryland, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
Missouri, United States
Nebraska, United States
Nevada, United States
New Jersey, United States
New York, United States
North Carolina, United States
Ohio, United States
Oklahoma, United States
South Carolina, United States
Tennessee, United States
Texas, United States
Utah, United States
Virginia, United States
Washington, United States
West Virginia, United States
Wisconsin, United States
Argentina
Australia
Austria
Belgium
Brazil
Canada
China
Colombia
Czechia
Denmark
Finland
France
Germany
Greece
Hong Kong
Ireland
Italy
Korea, Republic of
Malaysia
Mexico
Netherlands
Poland
Portugal
Puerto Rico
Romania
Singapore
Spain
Taiwan
Thailand
United Kingdom
No
Yes
Yes
Recruiting
cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849
NCT05482516
Phase 3
2022-08-01
District of Columbia, United States
No
No
Yes
Recruiting
Atezolizumab, Bevacizumab, Avastin, Tecentriq
MSS/ pMMR
NCT05141721
Phase 2, Phase 3
2021-12-02
Arizona, United States
Arkansas, United States
California, United States
Colorado, United States
Connecticut, United States
Florida, United States
Illinois, United States
Indiana, United States
Kansas, United States
Kentucky, United States
Maryland, United States
Michigan, United States
Nevada, United States
New Jersey, United States
New York, United States
North Carolina, United States
Ohio, United States
Oregon, United States
Pennsylvania, United States
South Carolina, United States
Tennessee, United States
Texas, United States
Utah, United States
Virginia, United States
Wisconsin, United States
No
No
Yes
Recruiting
Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin
MSS/ pMMR
NCT04607421
Phase 3
2020-10-29
Arizona, United States
California, United States
District of Columbia, United States
Florida, United States
Georgia, United States
Illinois, United States
Louisiana, United States
Michigan, United States
Minnesota, United States
Missouri, United States
Montana, United States
Nebraska, United States
New Jersey, United States
New York, United States
North Carolina, United States
Ohio, United States
Oklahoma, United States
Oregon, United States
Pennsylvania, United States
Tennessee, United States
Texas, United States
Virginia, United States
Washington, United States
Wisconsin, United States
Argentina
Australia
Belgium
Brazil
Bulgaria
Canada
China
Czechia
Denmark
Finland
Germany
India
Italy
Japan
Korea, Republic of
Mexico
Netherlands
New Zealand
Norway
Poland
Russian Federation
Slovakia
South Africa
Spain
Sweden
Taiwan
Ukraine
United Kingdom
No
No
Yes
Recruiting
5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin
MSS/ pMMR
NCT05328908
Phase 3
2022-04-14
Arkansas, United States
California, United States
Connecticut, United States
Florida, United States
Georgia, United States
Idaho, United States
Illinois, United States
Indiana, United States
Massachusetts, United States
Michigan, United States
Minnesota, United States
New Jersey, United States
North Carolina, United States
Ohio, United States
Pennsylvania, United States
South Carolina, United States
South Dakota, United States
Tennessee, United States
Texas, United States
Virginia, United States
Wisconsin, United States
Argentina
Australia
Austria
Belgium
Canada
Chile
China
Czechia
France
Germany
Italy
Japan
Korea, Republic of
Netherlands
Poland
Puerto Rico
Singapore
Spain
Sweden
Switzerland
Taiwan
No
No
Yes
Recruiting
Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga
MSS/ pMMR
NCT05223673
Phase 3
2022-02-04
Michigan, United States
Ohio, United States
Belgium
Denmark
Finland
Japan
No
No
Yes
Terminated
Futuximab/modotuximab, Trifluridine/Tipiracil
NCT05425940
Phase 3
2022-06-21
Alabama, United States
Arizona, United States
California, United States
Florida, United States
Georgia, United States
Illinois, United States
Indiana, United States
Kansas, United States
Kentucky, United States
Louisiana, United States
Missouri, United States
Montana, United States
Nebraska, United States
New Mexico, United States
New York, United States
North Carolina, United States
Ohio, United States
Oklahoma, United States
Oregon, United States
Pennsylvania, United States
South Carolina, United States
Tennessee, United States
Virginia, United States
Washington, United States
Australia
Belgium
France
Germany
Hong Kong
Hungary
Korea, Republic of
New Zealand
Poland
Portugal
Singapore
Spain
Taiwan
Thailand
No
No
Yes
Recruiting
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq
MSS/ pMMR
NCT04776148
Phase 3
2021-03-01
California, United States
Georgia, United States
Illinois, United States
Maryland, United States
Michigan, United States
Montana, United States
Oregon, United States
Pennsylvania, United States
Virginia, United States
Washington, United States
Argentina
Australia
Canada
China
Denmark
Germany
Israel
Japan
Korea, Republic of
Russian Federation
Spain
Taiwan
Turkey
United Kingdom
No
No
Yes
Active, not recruiting
Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)
MSS/ pMMR